PExA (PEXA) Q3 2026 earnings summary

Executive summary

• Q3 revenue was SEK 6,775; the nine-month period recorded SEK 1.20m, while net losses narrowed YoY in both periods. Cash rose to SEK 23.6m after July equity issues.

• Two studies strengthened scientific validation: Australian research found proteins from PExA samples also present in invasive lung lavage, and Karolinska researchers measured virus-specific antibodies in small-airway samples.

Financial highlights

• Q3 net sales were SEK 6,775 vs SEK 44,489 YoY; 9M net sales were SEK 1,195,334 vs SEK 357,069.

• Q3 net loss was SEK 1.53m vs SEK 2.57m; 9M net loss was SEK 3.73m vs SEK 7.14m. Q3 operating loss was SEK 1.57m vs SEK 2.58m.

• EPS was -SEK 0.01 in Q3 vs -SEK 0.04, and -SEK 0.03 for 9M vs -SEK 0.11.

• Q3 operating cash flow was SEK 160,616 vs -SEK 2.03m; total Q3 cash flow was SEK 22.82m vs SEK 6.37m.

Outlook and guidance

• Strategy focuses on Biomarker Discovery, pharmacokinetics/pharmacodynamics (PK/PD), and future Diagnostics applications; no quantitative financial targets were stated.

• A pharma agreement worth ~SEK 7.5m covers rental of ten systems for an international pulmonary-fibrosis study; €325,000 was invoiced and received, with revenue recognized over the rental period.

• Management expects stronger scientific evidence, broader international use, and new applications to support commercial opportunities in biomarker research, drug development, vaccine research, and future diagnostics.